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Abstract This paper examines the location of a secondary 
binding site for Cls on Cl-inhibitor (Cl-inh) which is required 
for the formation of SDS-stable Cls-Cl-inh complexes. We used 
a synthetic peptide (residues 448-459) corresponding to the distal 
hinge region of Cl-inh. This peptide binds to Cls and Cls 
preincubated with the peptide cleaves Cl-inh but does not form a 
stable Cls-Cl-inh complex. Computer modelling of Cl-inh 
shows that residues Q452, Q453 and F455 are surface-exposed 
and that the secondary binding site may also include residues 
H291 and F292 which are conserved in serpins. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Cl-inhibitor (Cl-inh) regulates the enzymatic activities of 
the Clr and Cls proteases of the complement system [1] in 
addition to regulating activities of activated Hageman factor 
[2], coagulation factor XIa, tissue plasminogen activator [3] 
and kallikrein [4]. Cl-inh belongs to the serpin family of ser-
ine protease inhibitors which includes most of the protease 
inhibitors found in blood as well as non-inhibitory proteins 
such as angiotensinogen [5,6] and ovalbumin [7-9]. Serpins 
inhibit proteases by forming a stable complex with them. 
The mechanism of complex formation is imperfectly under-
stood, but the serpin appears to act as a pseudosubstrate: the 
protease cleaves the serpin at a susceptible peptide bond 
(R444-T445 in the case of Cl-inh), but the products of cleav-
age do not dissociate. Instead an enzyme-product complex is 
formed, which is stable during analysis by SDS-PAGE. The 
protease must therefore have interactions with the serpin, ad-
ditional to the simple recognition of the region of the bond to 
be cleaved. In type II acquired Cl-inh deficiency, autoanti-
bodies against Cl-inh are present in the serum [10,11]. In 
most cases these autoantibodies cause the inhibitor to behave 
as a substrate, and no stable complex is formed. The patient's 
Cl-inh is cleaved and inactivated, giving rise to symptoms 
similar to hereditary deficiency of Cl-inh [12,13]. Recently 
we described six patients with type II Cl-inh deficiency in 
whom autoantibodies were shown to recognise the epitope 
QQPF in the distal hinge region of Cl-inh [14]. It was postu-
lated that the autoantibodies may inhibit a secondary inter-
action of Cls with Cl-inh which is essential for stable serpin-
protease complex formation. Our data confirm this hypothesis 
as Cls, like anti-Cl-inh autoantibodies, binds to a synthetic 
peptide derived from the distal hinge region of Cl-inh, and 
although the same peptide does not inhibit cleavage of Cl-inh 
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by Cls, it prevents the formation of a stable Cls-Cl-inh com-
plex. 
2. Materials and methods 
One IgG anti-Cl-inh autoantibody (from patient 1 in reference [14]) 
was affinity-purified using Cl-inh-Sepharose [13]. 
Three overlapping synthetic peptides (Fig. IB) spanning the prox-
imal hinge region (peptide 1, residues 428^140), the reactive site res-
idue (peptide 2, residues 438^149) and the distal hinge region (peptide 
3, residues 448^159) were obtained from Alta Biosciences, (University 
of Birmingham, UK). The anti-Cl-inh autoantibody used in this 
study, like the other five anti-Cl-inh autoantibodies studied previ-
ously, recognises the QQPF sequence (residues 452^155) in peptide 
3 but also recognises a structurally similar motif LLVF (residues 
446^149) in peptide 2 [14]. 
Activated Cls [15] and Cl-inh [16] were purified by standard tech-
niques. 
Binding of Cls to solid phase synthetic peptides and Cl-inh was 
determined by ELISA. Briefly plates were coated with peptides at 100 
ug/ml or Cl-inh at 5 ug/ml. Cls was used at 10 ug/ml. Bound Cls was 
detected using goat anti-human Cls (Incstar Ltd., Wokingham, UK) 
followed by the HRP-conjugated rabbit anti-goat IgG. 
Effects of peptides and the anti-Cl-inh autoantibody on Cls-Cl-inh 
interactions were studied using reagents diluted in PBS containing 1% 
(v/v) Triton X-100. Reaction products were analysed by SDS-PAGE 
and Western blotting [17]. Full details are given in the figure legends. 
Effects of synthetic peptides or Cl-inh on Cls activity were also 
analysed using the chromogenic substrate propionyl L-lysyl L-arginine 
p-nitroamlide hydroacetate (AcOH-C2H6CO-Lys(e-Cbo)-Gly-Arg-
pNA) (Immuno Ltd., Heidelberg, Germany) dissolved in 50 mM 
Tris-HCl, pH 8.5, containing 25 mM NaCl [13]. 
The secondary Cls binding site on Cl-inh was modelled by com-
puter graphics [18-20]. Graphics were created using the X-ray crys-
tallographic database of anti-thrombin III, provided by Professor R. 
Carrell (University of Cambridge, UK). Residue replacements were 
made according to serpin sequence alignments (Fig. 4B). 
3. Results and discussion 
Fig. 1A shows that 125I-labelled Cls forms an SDS-resistant 
complex with Cl-inh. In Fig. 1C it is seen that Cls binds most 
effectively to peptide 2, which contains the reactive site resi-
due. However, it also binds to peptide 3 which contains the 
epitope QQPF (residues 452-455) which is recognised by the 
anti-Cl-inh autoantibodies [14]. Computer modelling shows 
that Q452, Q453 and F455 are exposed on the surface of 
the Cl-inh molecule whereas P454 is concealed. In prelimi-
nary experiments using substituted peptides, we have demon-
strated that the replacements of either Q452 or Q453 with E, 
N, D or L and replacement of F455 with L reduces binding of 
Cls by 10-100-fold, confirming that Q452-Q453 and F455 are 
critical for the binding of Cls to peptide 3. Thus it appears 
that these three residues, which are recognised by spontane-
ously occurring anti-Cl-inh autoantibodies, are also recog-
nised by Cls, possibly as part of a secondary interaction 
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Fig. 1. Co valent binding of Cl-inh to Cls, and binding of Cls to 
synthetic peptides. A: Complex formation between Cl-inh and 125I-
labelled Cls (6 (xg of each in a reaction volume of 40 ul). The sam-
ples in PBS-1% (v/v) Triton X-100 were incubated at 37°C for 2 h 
and then the reaction was stopped by addition of 1:1 (v/v) SDS-
PAGE sample buffer (4 M urea, 125 mM Tris-HCl, pH 6.8, 10% (v/ 
v) glycerol, 0.8% (w/v) SDS and 0.002% (w/v) bromophenol blue). 
Lane 1, 125I-labelled Cls and Cl-inh; lane 2, 125I-labelled Cls alone. 
The reaction products were separated in 7.5% SDS-PAGE (under 
non-reducing conditions) then the dried gel was exposed to X-ray 
film (Blue Sensitive Film Genetic Research Instrumentation Ltd, 
Dunmow, Essex, UK). The band seen at > 190 kDa in lane 1 is 
the complex of Cl-inh with intact Cls. The band at 87 kDa is in-
tact Cls. Bands at 55 kDa and below are degradation products of 
Cls. B: Synthetic peptide sequences synthesised by Alta Bioscience, 
Birmingham University, UK. A cysteine residue was added to the 
N-terminus of each peptide, with the aim of forming a disulphide-
linked dimer. C: The binding of Cls to peptides 1, 2 and 3 and Cl-
inh. The peptides (100 ul of 100 ug/ml) and Cl-inh (100 ul of 5 ug/ 
ml) were coated in 15 mM Na 2 C0 3 and 35 mM NaHC03, pH 9.6 
onto wells of an ELISA plate (Falcon, Becton and Dickinson Lab-
ware Company, Oxnard, USA) overnight at 4°C. Non-specific bind-
ing sites were blocked by addition of 2% (w/v) BSA in PBS and in-
cubation at 37°C for 1 h. Cls (100 ul, 10 (ig/ml in PBS) was added 
to each well and incubated at 37°C for a further 1 h followed by 
addition of goat anti-human Cls (Incstar Ltd, Wokingham, UK) 
(1:2000) at room temperature for 2 h. Anti-goat IgG conjugated 
with horseradish peroxidase (HRP) (1:4000) (Incstar Ltd) was then 
added and incubated at room temperature for a further 2 h. The 
plate was washed 3 times in PBS-0.2%o (w/v) Tween 20 (Sigma 
Chemical Co., Poole, UK) between each step. The plate was devel-
oped using OPD (2.1%) (w/v) o-phenylenediamine dihydrochloride 
(Sigma) in 22 mM sodium citrate, pH 5.0, 56 mM Na2HP04, and 
5% (v/v) H2O2. The reaction was stopped by addition of 4 M 
H2SO4 and the absorbance was read at 490 nm. The results are 
averages of 5 separate experiments each of which contained 5 repli-
cates. Although we have not determined the absolute amount, sig-
nificant binding of each peptide to ELISA plates was shown by the 
use of three peptide-specific murine monoclonal antibodies (Tsang 
and Whaley, unpublished data). 
site. Failure to demonstrate binding of C l s to peptide 1 was 
not due to poor binding of this peptide to the ELISA plates. 
Murine monoclonal antibodies to each of these peptides 
showed high levels of binding to the appropriate peptide 
bound to the same microtitre plate (Tsang and Whaley, un-
published data). Furthermore, the failure of peptide 1 to in-
terfere with (a) the formation of C l s -Cl - inh complexes (see 
below) and (b) Cls-mediated hydrolysis of a synthetic sub-
strate (Fig. 3) support the conclusion that there is no binding 
site for C l s in peptide 1. 
As peptides 2 and 3 (Fig. IB) contain binding sites for C l s 
(Fig. 1C), both should interfere with the interaction between 
C l s and Cl- inh . This was demonstrated by incubating each 
Fig. 2. Western blots of reaction products of Cls and Cl-inh in the 
presence of the peptides. Cls and Cl-inh (6.0 ug of each) were dis-
solved in PBS-1%0 Triton X-100 in a total reaction volume of 40 ul. 
The reactions were stopped by addition of an equal volume of 
SDS-PAGE sample buffer (see legend to Fig. 1A) and the products 
were separated in 7.5% SDS-PAGE under reducing and non-reduc-
ing conditions. The proteins were transferred to nitrocellulose mem-
branes (Hybond-Super, Amersham International pic, Little Chal-
font, UK), in 25 mM Tris/192 mM glycine buffer containing 20% 
(v/v) methanol and 0.1% SDS at 4°C using a current of 200 mA for 
6 h. After blotting the membrane was washed in 10 mM Tris-HCl 
(pH 8.0) containing 150 mM NaCl, 1 mM EDTA and 0.1% (v/v) 
Triton X-100 (rinse buffer). Membranes were then incubated (6 h at 
4°C) in blocking buffer (rinse buffer containing 2% w/v BSA (Sigma 
Chemical Co., Poole, UK) and 0.02%> (w/v) sodium azide (Sigma)) 
and were incubated for 2 h at 4°C with goat anti-human Cls or 
goat anti-human Cl-inh (both from Incstar Ltd., Wokingham, UK) 
diluted 1/2000 in blocking buffer, washed thrice in blocking buffer 
(15 min in 100 ml for each wash), incubated for 2 h at 4°C with 
peroxidase-labelled rabbit anti-goat IgG (Incstar) in blocking buffer, 
rewashed three times and finally developed using the ECL system 
(Amersham International pic) according to the manufacturer's in-
structions. The membrane was then exposed to high performance lu-
minescence detection film (Hyperfilm ECL, Amersham International 
pic). A: Western blot of reaction products of Cls and Cl-inh inter-
action in the presence of peptide 2 using reducing SDS-PAGE 
(7.5%). Blots were probed with goat anti-human Cls. Lane 1, Cls 
and Cl-inh incubated at 37°C for 2 h; lanes 2-6, incubated with 
peptide 2 at molar ratios of 3:1 (lane 2), 2:1 (lane 3), 1:1 (lane 4), 
1:1.6 (lane 5), 1:3 (lane 6) at 37°C for 1 h before Cl-inh was added 
to the mixture and incubation continued at 37°C for a further 2 h. 
B: Western blot (7.5% SDS-PAGE, non-reducing conditions) of re-
action products of Cls and Cl-inh in the presence of peptide 3. 
Blots were probed with goat anti-human Cl-inh. Lane 1, Cl-inh 
alone incubated at 37°C for 2 h; lane 2, Cl-inh and Cls incubated 
at 37°C for 2 h; lane 3, Cl-inh incubated with anti-Cl-inh autoanti-
body at a molar ratio 1:1 at 37°C for 1 h and then Cls for a fur-
ther 2 h; lanes 4 and 5, Cls incubated with peptide 3 (1:3 and 1:5 
molar ratios, respectively) at 37°C for 1 h and then with Cl-inh for 
a further 2 h. Note that the 96 kDa bands were increased and the 
115 kDa bands decreased in the presence of either anti-Cl-inh auto-
antibody or peptide 3 compared with Cl-inh alone (lane 1). C: 
Western blot (7.5% SDS-PAGE, non-reducing conditions) of reac-
tion products of Cls and Cl-inh in the presence of peptide 2. Lane 
1, Cl-inh and Cls incubated at 37°C for 2 h; lanes 2-4, Cls incu-
bated with peptide 2 (1:5, 1:3 and 1:1 molar ratios, respectively) at 
37°C for 1 h and then with Cl-inh for a further 2 h. Note that the 
115 kDa band in lane 1 was decreased due to the formation of Cls-
Cl-inh complex ( > 190 kDa band). However, unlike the situation 
with peptide 3 (B), increased cleavage of the Cl-inh did not occur 
as shown by the relative intensities of the 115 kDa and 96 kDa 
bands in lanes 2-A compared with lanes 3-5 in B. 
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Inhibition of Cls by synthetic peptides 
(Cls activity (%)) 
Concentrations 
12uM 24uM 
Peptide 1 9S.35+0.82 96.23±1.57 
Peptide 2 39.59+0.75 19.54+0.92 
Peptide 3 76.73±0.81 58.22±1.23 
Fig. 3. Assays of the effect of the synthetic peptides on Cls enzymic 
activity. The effect of the synthetic peptides on Cls enzymic activity 
was assayed using the chromogenic substrate, propionyl L-lysyl L-ar-
ginine ^-nitroanilide hydroacetate (AcOH-C2H5CO-Lys(e-Cbo)-Gly-
Arg-pNA) (Immuno Ltd., Heidelberg, Germany) which was dis-
solved in 50 mM Tris-HCl, pH 8.5, 25 mM NaCl. The concentra-
tion of Cls was kept constant at 8 uM and peptides were at a final 
concentration of 12 |iM and 24 uM. Cls was dissolved in 10 mM 
Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA and incubated with 
peptides at 37°C for 20 min before addition of the chromogen to 
the final concentration of 10 uM in each reaction. The absorbance 
changes were recorded automatically at 37°C. Cls activity (%) was 
calculated using 1—[(slope of Cls alone—slope of Cls and peptide)/ 
slope of Cls alone] X 100. 
peptide with Cls prior to the addition of Cl-inh. In the ab-
sence of peptide or in the presence of peptide 1, a stable Cls-
Cl-inh complex was formed as demonstrated by SDS-PAGE 
followed by immunoblotting, using anti-Cls as a probe. This 
shows that (a) peptide 1 does not bind to Cls and (b) pre-
incubation of Cls for 1 h prior to the addition of Cl-inh did 
not affect complex formation. In the presence of peptide 2 a 
stable Cls-Cl-inh complex was not formed, and the inhibitory 
effect of peptide 2 was shown to be dose-dependent (Fig. 2A). 
An identical result was obtained when peptide 3 was substi-
tuted for peptide 2 (data not shown). When the same experi-
ments were repeated using anti-human Cl-inh as a probe for 
the immunoblots, the absence of the Cls-Cl-inh complex in 
reaction mixtures containing peptides 2 and 3 was confirmed 
(Fig. 2B,C). However, in contrast to the peptide 2 reaction 
mixture which contained Cl-inh with the normal Mr of 115 
kDa, Cl-inh in the peptide 3 reaction mixture was in the 
cleaved 96 kDa form (Fig. 2B), indicating that peptide 3 
had 'converted' Cl-inh to a substrate. The same effect was 
seen when the affinity-purified anti-Cl-inh autoantibody was 
substituted for peptide 3 (Fig. 2B, lane 3). Although peptide 2 
prevented the formation of the Cl-inh-Cls complex, it did not 
'convert' Cl-inh to a substrate (Fig. 2C). The inhibitory ac-
tivity of the peptides was investigated further by demonstrat-
ing their effect on the activity of Cls in cleaving synthetic 
substrates (Fig. 3). Peptide 2, which contains the sequence 
normally cleaved by Cls, inhibited complex formation be-
tween Cl-inh and Cls, and is therefore likely to act as a 
competing (pseudo)substrate by inhibiting recognition by 
Cls of the R444-T445 site in Cl-inh, and preventing the initial 
cleavage of Cl-inh. Peptide 3, however, was a much less po-
tent inhibitor of Cls enzymic activity against the chromogenic 
substrate (Fig. 3), but it effectively inhibited Cls-Cl-inh com-
plex formation, and, like the autoantibody, it promoted the 
generation of uncomplexed, cleaved Cl-inh. The observations 
that peptide 3 (a) bound to Cls, (b) prevented Cls-Cl-inh 
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complex formation but (c) did not inhibit the cleavage of 
Cl-inh by Cls and (d) was not an effective inhibitor of hy-
drolysis of the chromogenic substrate by Cls are consistent 
with peptide 3 possessing a Cls binding site which prevents 
the binding of Cls to the residues QQ-F in the Cl-inh mol-
ecule, which contribute a secondary Cls binding site. 
Computer modelling of Cl-inh (Fig. 4A) indicates that the 
residues Q452, Q453 and F455 are closely adjacent on the 
surface of the molecule. Interestingly Q452 is immediately 
adjacent to, but partially conceals, F291, which, like F455, 
is highly conserved amongst the serpins (Fig. 4B). H292, 
which is also highly conserved amongst the serpins, is also 
adjacent to Q452 and Q453 and is exposed on the surface 
of the molecule. It is possible that residues F291, F455 and 
H292 contribute to the secondary interaction site but the spe-
cificity is determined by Q452 and Q453. Thus our data sug-
gest that the binding of an anti-Cl-inh autoantibody to its 
epitope on Cl-inh would, like the binding of peptide 3 to 
Cls, prevent the interaction of Cls with this critical secondary 
binding site therefore converting Cl-inh to a substrate and 
producing acquired Cl-inh deficiency. It is also possible that 
the conserved residues F291, H292 and F455 comprise part of 
a secondary enzyme binding site in all serpins with serine 
protease inhibitory activity but with enzyme specificity being 
determined by the equivalent residues to 452 and 453 in Cl-
inh. 
Although the distal hinge region of Cl-inh contains a sec-
ondary Cls binding site which is essential for the formation of 
a stable enzyme-inhibitor complex, residues in the proximal 
hinge region must also contribute to this as mutations in this 
region (e.g. V432E) [21] may also produce Cl-inh deficiency 
by converting Cl-inh to a substrate. However, in this case the 
mechanism is unlikely to be related to the binding of Cls to 
residues in the proximal hinge region, as Cls did not bind to 
peptide 1. How residues in the proximal hinge region contrib-
ute to the formation of a stable enzyme-inhibitor complex 
merits further investigation. 
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